Prostate-specific antigen ratio correlates with aggressiveness of histology grades of prostate cancer

Clinical Biochemistry

Volumn 32, Issue 1, 1999, Pages 31-37

  Li, Wei ^a   Ren, Ying ^a   Mee, Vicky ^a   Wong, Pui Yuen ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Histology grade; Prostate cancer, total PSA; PSA ratio

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN SPECIFICITY; ARTICLE; CANCER GRADING; CANCER INVASION; DRUG BLOOD LEVEL; EARLY DIAGNOSIS; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TISSUE SPECIFICITY;

AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0032973049     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(98)00088-5     Document Type: Article

References (34)

1. Gann P.H., Hennekens C.H., Stampfer M.J. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 273:1995;289-294.
2. Hudson M.A., Bahnson R.R., Catalona W.J. Clinical use of prostate- specific antigen in patients with prostate cancer. J Urol. 142:1989;1011-1017.
3. Lange P.H., Ercole C.J., Lightner D.J., Fraley E.E., Vesella R. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol. 141:1989;873-879.
4. Mettlin C., Littrup P.J., Kane R.A., et al. Relative sensitivity and specificity of serum prostate-specific antigen levels compared with age-referenced PSA, PSA density, PSA change. Cancer. 74:1994;1615-1620.
5. Narayan P., Fournier G., Gajendran V., et al. Utility of preoperative serum prostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer. Urology. 44:1995;519-524.
6. Bostwick D.G., Qian J., Bergstralh E., et al. Prediction of capsular perforation and seminal vesicle invasion in prostate cancer. J Urol. 155:1996;1361-1367.
7. Partin A.W., Kattan M.W., Subong E.N., et al. Combination of prostate-specific antigen, clinical stage, Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 277:1997;1445-1451.
8. Roach M. 3rd, Marquez C., Yuo H.S., et al. Predicting the risk of lymph node involvement using the pre-treatment prostate-specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 28:1994;33-37.
9. Christensson A., Laurell C.B., Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem. 194:1990;755-763.
10. Stenman U.H., Leinonen J., Alfthan H., et al. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer. assay of he complex improves clinical sensitivity for cancer. Cancer Res. 51:1991;222-226.
11. Prestigiacomo A.F., Lilja H., Pettersson K., Wolfert R.L., Stamey T.A. A comparision of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates the best case senario . J Urol. 156:1996;350-354.
12. Leinonen J., Lovgren T., Sternman U.H. Double-label time resolved immunofluorometric assay of prostate-specific antigen and its complex with alpha-1-antichymotrypsin. Clin Chem. 39:1993;2098-2103.
13. Mitrunen K., Pettersson K., Piironen T., et al. Dual-label one-step immunoassay for simultaneous measurement of free and total PSA concentrations and ratios in serum. Clin Chem. 41:1995;1115-1119.
14. Demura T., Shinohara N., Tanaka M., et al. Ratio of free and total prostate-specific antigen a method of detecting prostate cancer in the cases with PSA levels of 10 ng/ml or lower (abst) . J Urol. 155:1996;368A.
15. Elgamel A.A., Cornillie F., Van Poppel H., et al. Free/total PSA ratio (F/T) as a single test for detection of significant T1c prostate cancer (abst). J Urol. 155:1996;369A.
16. Reissigl A., Klocker H., Pointer J., et al. Improvement of prostate cancer (PCA) screening by determination of the ratio free/total (F/T) PSA in addition to PSA levels. A prospective study. J Urol. 155:1996;370A.
17. Miller M.I., Katz A.E., Ikeguchi E., et al. Patient outcome when free total PSA, PSA density and PSA velocity are utilized to improve serum PSA specificity: A 5 year study . J Urol. 155:1996;371A.
18. Partin A.W., Subong E.N.P., Kelley C.A., et al. Prospective analysis of free PSA to total prostate PSA ratio (PSAf/PSAt) for prostate cancer detection and the clearance rate of PSAf after radical prostectomy. J Urol. 155:1996;417A.
19. Saito S., Ozu C., Nakamura K., et al. Screening of prostate cancer with free and total prostate specific antigen (PSA) ratio. J Urol. 155:1996;373A.
20. Christensson A., Bjork T., Nilsson O., et al. Serum prostate-specific antigen complexed to a1-antichymotrypsin as an indicator of prostate cancer. J Urol. 150:1993;100-105.
21. Catalona W.J., Smith D.S., Wolfert R.L., et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 274:1995;1214-1220.
22. Pearson J.D., Partin A.W., Chan D.W., Luderer A.A., Carter H.B. Serial measurements of serum total PSA, free PSA, free/total PSA ratio in men with and without prostate disease (abst). J Urol. 155:1996;606A.
23. Carter H.B., Pearson J.D., Metter J.E., et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 267:1992;2215-2220.
24. Carter H.B., Partin A.W., Luderer A.A., et al. Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology. 49:1997;379-384.
25. Graefen M., Hammerer P., Henke P., et al. Percentage of free PSA does not correlate with pathology outcome (abst). J Urol. 155:1996;370A.
26. Catalona W.J., Partin A.W., Slavin K.M., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostate disease A prospective multicenter clinical trial . JAMA. 279:1998;1542-1547.
27. Lerner S.E., Jacobsen S.J., Bergstrahl E.J., et al. Free, complexed, and total serum PSA concentrations and their proportions in predicting stage, grade, and DNA ploidy in patients with prostate cancer (PC) (abst). J Urol. 155:1996;416A.
28. Stamey T.A., Yang N., Hay A.R., et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 317:1987;909-916.
29. Monda J.M., Barry M.J., Oesterling J.E. Prostate-specific antigen cannot distinguish stage T1a prostate cancer from benign prostate hyperplasia. J Urol. 15:1994;1291-1295.
30. Vash A.R., Wojno K.J., Henricks W., et al. Determination of the "reflex range" and appropriate cutpoints for percent free prostate specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology. 49:1997;19-27.
31. Roehrborn C.G., Issa M.M., Bruskewitz R.C., et al. Transurethral needle ablation for benign prostatic hyperplasia 12-month results of prospective, multicenter U.S. study . Urology. 51:1998;415-421.
32. Steinberg D.M., Sauvageot J., Piantadosi S., Epstein J.I. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community setting. Am J Surg Pathol. 21:1997;566-576.
33. Hepap B. Pathologie der ableitenden harnwege und der prostata. 1989;Springer-Verlag, Heidelberg.
34. Tarle M., Kraljic I. Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BDH. Is F/T PSA a potential probe for dormant and manifest cancer? Anticancer Res. 17:1997;1531-1534.